Bivalirudin in Venovenous Extracorporeal Membrane Oxygenation

View Full Paper

Ask AI

Bookmark

Population

1 patient on venovenous extracorporeal membrane oxygenation with heparin resistance resulting from…

Design

Case_report

Authors

Discussion

May support bivalirudin in heparin-resistant VV-ECMO; hypothesis-generating and requires prospective validation.

Population

1 patient on venovenous extracorporeal membrane oxygenation (ECMO) with heparin resistance resulting from antithrombin III deficiency

Intervention

Bivalirudin at a dose of 0.1-0.2 mg/kg/h

Outcome

Maintenance of target activated clotting time (ACT) of 200-220 seconds and occurrence of bleeding or thrombotic complicationssafety

Bivalirudin appears to be a feasible, effective, and safe alternative anticoagulant for patients on venovenous ECMO who develop heparin resistance.

Jyoti et al. (2014) studied this question.

View Full Paper

Ask AI

Bookmark